What's in Fundación Santiago Dexeus Font's pipeline?

Fundación Santiago Dexeus Font has 7 drugs in our index: 7 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Fundación Santiago Dexeus Font's portfolio?

Top competitors by shared drug class: Ain Shams Maternity Hospital, Azienda USL Modena, Bezmialem Vakif University, Central Jutland Regional Hospital, Centre Hospitalier Intercommunal Creteil.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/fundaci-n-santiago-dexeus-font.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Fundación Santiago Dexeus Font — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fundación Santiago Dexeus Font pipeline: 7 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

7 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Ovulation triggering with GnRH-a	Ovulation triggering with GnRH-a	marketed
Cellular Matrix / A-CP-HA Kit	Cellular Matrix / A-CP-HA Kit	marketed	Cell therapy / Regenerative medicine product		Regenerative Medicine / Orthopedics
rhFSH	rhFSH	marketed	Gonadotropin	FSH receptor (FSHR)	Reproductive Medicine / Fertility
Ovarian Stimulation with rFSH	Ovarian Stimulation with rFSH	marketed	Gonadotropin	FSH receptor (FSHR)	Reproductive Medicine / Fertility
rhFSH+rhLH	rhFSH+rhLH	marketed	Gonadotropin	FSH receptor and LH receptor	Reproductive/Fertility
Ovarian Stimulation with CC+rFSH	Ovarian Stimulation with CC+rFSH	marketed	Gonadotropin combination therapy	FSH receptor (FSHR); estrogen receptor (ER) antagonism	Reproductive Medicine / Fertility
Ovulation triggering with GnRH-a+rhCG	Ovulation triggering with GnRH-a+rhCG	marketed	Gonadotropin-releasing hormone agonist combined with recombinant human chorionic gonadotropin	GnRH receptor (for GnRH-a component); LH/hCG receptor (for rhCG component)	Reproductive Medicine / Fertility

Therapeutic area mix

Reproductive Medicine / Fertility · 4
Regenerative Medicine / Orthopedics · 1
Reproductive/Fertility · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Ain Shams Maternity Hospital · 1 shared drug class
Azienda USL Modena · 1 shared drug class
Bezmialem Vakif University · 1 shared drug class
Central Jutland Regional Hospital · 1 shared drug class
Centre Hospitalier Intercommunal Creteil · 1 shared drug class
D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology · 1 shared drug class
Dunamenti REK Istenhegyi IVF Center · 1 shared drug class
AGUNCO Obstetrics and Gynecology Centre · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Fundación Santiago Dexeus Font:

Cite this brief

Drug Landscape (2026). Fundación Santiago Dexeus Font — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/fundaci-n-santiago-dexeus-font. Accessed 2026-05-17.